(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 May 2015 (21.05.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/071380 A1

(51) International Patent Classification:
A61K 31/485 (2006.01) *A61P 29/00* (2006.01)
A61K 45/06 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:
PCT/EP2014/074537

(22) International Filing Date:
13 November 2014 (13.11.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13192793.1 13 November 2013 (13.11.2013) EP

(71) Applicant: **EURO-CELTIQUE S.A.** [LU/LU]; 2, avenue Charles de Gaulle, L-1653 Luxembourg (LU).

(72) Inventors: **DANAGHER, Helen, Kathleen**; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge, Cambridgeshire CB4 0GW (GB). **MOHAMMAD, Hassan**; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge, Cambridgeshire CB4 0GW (GB). **WALDEN, Malcolm**; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge, Cambridgeshire CB4 0GW (GB). **HAYES, Geoffrey, Gerard**; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge, Cambridgeshire CB4 0GW (GB). **WHITEHOUSE, Jonathon, Oliver**; Mundipharma Research Limited, 191 Cambridge Science Park Milton Road, Cambridge, Cambridgeshire CB4 0GW (GB). **KRISHNAMURTHY, Thinnayam, Naganathan**; 168 Bonis Avenue, Apartment #711, Scarborough, Ontario M1T 3V6 (CA). **VARGAS RINCON, Ricardo, Alberto**; 6602 Harmony Hill, Mississauga, Ontario L5W 1S4 (CA).

(74) Agent: **BÜHLER, Dirk**; MAIWALD PATENTANWALTS GMBH, Elisenstrasse 3, Elisenhof, 80335 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/071380 A1

(54) Title: HYDROMORPHONE AND NALOXONE FOR TREATMENT OF PAIN AND OPIOID BOWEL DYSFUNCTION SYNDROME

(57) Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.